Teos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of differentiated immuno-oncology therapeutics for patients. The company is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
iTeos leverages its understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with the aim of improving outcomes for cancer patients. Two drug candidates, inupadenant (EOS-850) and EOS-448, each targeting a key mechanism that inhibits an effective antitumor immune response, namely the adenosine pathway and a novel checkpoint TIGIT, are currently in clinical trials. With a deep understanding of the critical immune resistance pathways, iTeos aims to identify new targets and generate additional programs for underexploited pathways validated by a strong scientific rationale.
Yvonne McGrath, PhD – Vice President of R&D